A recent study found that treatment with a systemic JAK1/2 inhibitor was associated with weight gain, the development of obesity, and increased systolic blood pressure.
A recent study examined the metabolic effects of ruxolitinib in patients with myeloproliferative neoplasms (MPNs). Previous studies have reported that ruxolitinib treatment was linked with weight gain, but other metabolic effects are unknown.
Ruxolitinib, a tyrosine kinase inhibitor (TKI) that inhibits Janus kinase (JAK) 1/2, is approved by the FDA to treat certain MPNs, including myelofibrosis (MF) and polycythemia vera (PV). The JAK family kinases are targeted in cancers due to their role in cytokine receptor signal transduction, and are also key intermediates in growth hormone, leptin, and prolactin receptor signaling.
In this study, researchers identified patients from a database of electronic medical records (EMRs). The patients had started treatment with ruxolitinib for MPN from December 2011 to December 2016. Data collected from EMRs included age, gender, weight, height, systolic and diastolic blood pressure (SBP, DBP), medications, comorbidities, random serum glucose, and lipid profile.
Parameters were compared from baseline (prior to initiating ruxolitinib) to 72 (8) weeks after starting treatment. Baseline and 72-week data were compared using the Wilcoxon signed rank test.
Of the 129 patients identified, 71 had data available for weight, and at least 1 other metabolic parameter of interest at baseline and 72 weeks. Patients were 49.3% male with a mean age at start of treatment of 64.6 (11.1) years. Disease indications for treatment were MF (77%), PV (17%), and other MPNs (6%).
Mean baseline weight was 73.6 (16.9) kg, and was 78.3 (8.9) kg at 72 weeks (n = 71, P <.001). Mean body mass index (BMI) at baseline was 25.6 (4.6) kg/m2, and 27.3 (5.4) kg/m2 at 72 weeks (n = 68, P <.001).
The BMI (kg/m2) distribution for underweight (<18.5), normal (18.5-24.9), overweight (25-29.9), and obese (>30) at baseline were: 3%, 43%, 41%, and 13%, respectively. At 72 weeks it was 1%, 40%, 34%, and 28%, respectively (P = .002). At 72 weeks, 19% of the patients moved up a BMI class from baseline.
The effect of ruxolitinib was also examined for treatment on blood pressure and glucose concentrations. SBP was 124/15 mmHg at baseline and 129/18 mmHg at 72 weeks, (P = .042, n = 71). DBP was not different between baseline and 72 weeks.
Glucose at baseline was 99 (28) mg/dL and 101 (29) mg/dL at 72 weeks (P = .015, n = 59). There was no change in the percent of patients with hyperglycemia (glucose ≥200 mg/dL) or on treatment for diabetes at baseline (13.6%) and 72 weeks (13.6%). An insufficient number of patients had lipid data available for analysis.
In this group of patients, treatment with a systemic JAK1/2 inhibition was associated with weight gain, the development of obesity, and increased SBP.
The researchers said it is important to get an improved understanding of these therapies as they become more widely used.
Reference
Sapre M, Tremblay D, Leiter A, et al. SAT-091 metabolic effects of JAK1/2 inhibition in patients with myeloproliferative neoplasms. J Endocr Soc. 2019; 3(1) doi: 10.1210/js.2019-SAT-091.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
November 21st 2023Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Odevixibat Safe for Alagille Syndrome Based on Hepatic Changes
November 8th 2023Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen